Global Transfection Reagents and Equipment Market - 2022-2029

Global Transfection Reagents and Equipment Market - 2022-2029

Market Overview

Transfection Reagents and Equipment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.45 % during the forecast period (2022-2029).

Transfection is a process that involves the production of genetically modified cells with the utilization of foreign nucleic acid (DNA and RNA). Transfection is essential equipment used in investigation studies for gene function and the modulation of gene expression. The transfection reagents and equipment market is driven by the rising incidence of infectious diseases, increase in the R&D expenditure and research activities by the pharmaceutical and biotechnology companies, technological advancements in transfection, increasing incidence of cancer, and the presence of various government initiatives.

Market Dynamics: Increasing incidence of cancer drive market growth.

The rising incidence of cancer is one of the dominating factors propelling the global transfection reagents and equipment market. For instance, According to WHO, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020 globally. Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Thus, the rising incidences of cancer are driving the market.

Also, infectious diseases represent a significant health problem worldwide in terms of morbidity and mortality. A complex combination of environmental, pathogen, and host genetic factors plays a role in determining both susceptibilities to microbes and the course of infection. Also, the number of emergency department visits resulting in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases increased. Thus, the rising incidence of infectious diseases is driving the market.

Further, in recent times, the biopharmaceutical industry has seen a significant patent cliff as several blockbuster biologics are facing patent expiration. Consequently, several companies have begun investing in producing biosimilar alternatives to off-patent biologics to overcome the threat of revenue loss. Hence, the patent cliff threat has significantly benefitted the market by spurring the adoption rate of transfection technology.

However, the high cost of transfection reagents and equipment, risk factors during insertion of the reagents, selective effectiveness and certain limitations of transfection reagents and cytotoxic effect associated with transfection technology are the major factors restraining the transfection reagents and equipment market.

The number of cells that the methods can effectively transfect, and the limited clinical and laboratory use, owing to the integration of viral vectors randomly into the genome producing significant bio-hazardous risks, are some of the limitations offered by the transfection reagents.

Market Segmentation: The reagent segment is projected to be the dominant segment in the market during the forecast period.

The reagents segment is sub-segmented into lipid-mediated transfection, DEAE-dextran, activated dendrimers, calcium phosphate, cationic polymers, and others. The reagents segment is expected to dominate the market over the forecast period. It is owing to the increasing commercial adoption rates of these reagents. For instance, OZ Biosciences revolutionized Polyfection with the design of Helix-IN, a novel patented Cationic Hydroxylated Amphiphilic Multi-block Polymer (CHAMP Technology). This novel bi-functional co-polymer is biocompatible, ionizable, pH-responsive, and biodegradable. Thus, the increased adoption of reagents owing to the presence of products is driving the market.

Transfection equipment can be sub-segmented into liposomes, electroporation, microinjection, laserfection, and others.

The equipment segment held a significant market share in the forecast period. The rapidly growing volume of genomics-based research and development initiatives and the introduction of user-friendly products like portable DNA sequencers are expected to propel the transfection reagent and equipment market during the forecast period. The presence of expensive laser-based equipment used for the different transfection methods like laserfection or optoinjection is estimated to drive the growth of the equipment segment.

The transfection reagents and equipment market can be segmented by application into biomedical research, protein production, and therapeutic delivery. Biomedical research is further sub-segmented into gene expression studies, cancer research, and transgenic models.

Biomedical research is expected to boost the market over the forecast period, owing to the increased adoption of reagents for biomedical research. For instance, AltoFect of Altogen biosystems transfection reagent enables the researchers to overcome the challenges and limitations of primary cells and difficult-to-transfect cell lines. Also, Gene expression studies were expected to be the most prominent application. The expansion of the genomic data pool and the growing emphasis on translating genomic information in the clinical workflow lead to a considerable share of this segment. The presence of a substantial number of ongoing research projects that aim at the in-depth investigation of key mechanisms, which underlie chromosomal anomalies, is also supplementing the growth of the segment.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is dominating the global transfection reagents and equipment market owing to the rising incidence of various cancers, the increasing demand for proteomics and genomics technology, and the upfront initiatives taken by the government related to preventive healthcare. The rising incidence of cancer is expected to boost the market. For instance, in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths will occur in the United States. Thus, the growing number of cancer cases is driving the market. The presence of upfront initiatives taken by the government related to preventive healthcare is expected to boost the market. For instance, the American cancer society has invested more than $4.8 billion in cancer research to find more and better treatments, uncover factors that may cause cancer, and improve cancer patients' quality of life. Also, the National Cancer Institute coordinated the National Cancer Program, which conducts and supports the research, health information dissemination, and other programs related to the prevention, cause, diagnosis, and treatment of cancer, rehabilitation from cancer, and continuous care of cancer patients. Thus, government initiatives for preventive healthcare are driving the market. Funding and federal agencies, like the National Science Foundation (NSF), offer the biotechnology sector huge funding to carry out biotechnology-based investigational studies. Moreover, international funding bodies like NIH and Welcome Trust are expected to play a vital role in the market growth by giving the funds for genetic research studies.

Competitive Landscape:

The key players operating in the global transfection reagents and equipment market are Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Illumina, Inc., Norgen Biotek Corp., QIAGEN, PerkinElmer Inc., OriGene Technologies Inc., Promega Corporation, and Thermo Fisher Scientific Inc. Some major key players follow merger and collaboration strategies to expand their business. For instance, in May 2022, Agilent announced a collaboration with APC on Real-Time Process Monitoring. Through this acquisition, both companies combined their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography. This collaboration strengthens services and technologies to the customers. In February 2022, Agilent acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that creates innovative analysis solutions in lab testing. This acquisition is an investment in digital technology to improve lab productivity. In August 2021, Illumina, the global leader in DNA sequencing, acquired GRAIL, a healthcare company focused on early life-saving detection of multiple cancers to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection tests. In August 2022, Merck acquired the Chemical Business of Mecaro, a Korea-based and publicly listed manufacturer of heater blocks and chemical precursors for semiconductors. Through this acquisition, Merk expands its Electronics business to further expand its regional capabilities and global capacity. This acquisition includes the investment of more than € 3 billion.

The global transfection reagents and equipment market report would provide an access to approximately 61 market data tables, 51 figures and 170 pages